TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06510348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental Parenteral Nutrition (SPN)
Description: Nutritional targets are based on ESPEN guidelines recommendation (calories administration based on indirect calorimetry study, proteins 1.3 g/kg/day). From the first day of ICU admission indirect calorimetry will be performed daily in order to evaluate energy requirements. On the fourth day, the patient will undergo a gastric residual volume measurement and a paracetamol absorption test. If gastrointestinal dysfunction is detected, the patient will be assigned to a study group based on the randomization protocol. The SPN group will gradually initiate supplemental parenteral nutrition in order to achieve the target of 80% by the fifth day. Trophic feed will be administered to cover the remaining 20% of the targeted nutrition intake.
Study: NCT05139277

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CONVIVO system
Description: Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional histologic evaluation
Description: Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
Study: NCT05386524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: sintilimab 200mg, ivgtt，d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab biosimilar
Description: bevacizumab biosimilar 15mg/kg，ivgtt d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: pegylated liposomal doxorubicin 30mg/m2 d1，q3w
Study: NCT06445218

Intervention type: OTHER
Intervention: Data collection
Description: Collection of various data from patients' medical file, such as demographic data, diagnostic results, discharge, treatment....
Study: NCT04897113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasma exchange with albumin
Description: plasma exchange with albumin, two per week, 110% of the circulating plasma volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasma exchange without albumin
Description: plasma exchange without albumin, two per week, 110% of the circulating plasma volume
Study: NCT06127017

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: splinting dental implants with titanium bar
Description: splinting of dental implants will be done in the placebo comparator group by welding a titanium bar intraorally to the temporary sleeves attached to the implants.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: splinting dental implants with PEEK bar
Description: in the active comparator group ,the PEEK bar will be attached to the temporary sleeves using flowable composite resin material.
Study: NCT05742919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC0194-0499
Description: Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
Study: NCT05077956

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal and Blood Serum Semaphorin 4A Levels
Description: Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal and Blood Serum Semaphorin 4A Levels
Description: Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal and Blood Serum Semaphorin 4A Levels
Description: Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal and Blood Serum Semaphorin 4A Levels
Description: Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
Study: NCT05824117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Description: IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning.
Study: NCT04694612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
Study: NCT05440331

Intervention type: OTHER
Intervention: Training with AnesList©
Description: Training with AnesList© as tool

Intervention type: OTHER
Intervention: Training with AnesList©
Description: Training with AnesList© as tool
Study: NCT04631744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily
Study: NCT05766189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wastewater vaccine prompts
Description: Social media communications showing levels of SARS-CoV-2 in wastewater
Study: NCT03833804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processing of clinical notes in the EHR data collected during routine care
Description: Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
Study: NCT06647017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volta tAN System
Description: Transcutaneous auricular neurostimulation (tAN)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Volta tAN System
Description: Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.
Study: NCT06065358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Patients with advanced suspected HGSOC will be considered eligible (FIGO stage from III C or greater). At the time of surgery, patients' disease extension will be assessed with the Fagotti score (PIV) and the Vizzielli score (VS). Only patients who are not considered operable in the first place, will be enrolled. Samples will be taken during surgery that will take place in the operating rooms of oncological gynaecology.
Study: NCT04191434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flamboyant 125/12
Description: Flamboyant 125/12 capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol 200/6
Description: Budesonid/formoterol 200/6 capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamboyant 125/12 Placebo
Description: Flamboyant 125/12 Placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 200/6 placebo
Description: Budesonid/formoterol 200/6 Placebo capsule
Study: NCT06068244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed crowns
Description: 3D printed crowns

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia crowns
Description: Nu smile zirconia crowns
Study: NCT05831007

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX102-C01 Injection
Description: Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial.
Study: NCT05863195

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT and/or CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo SPECT/CT and/or CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Given via HAI pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Undergo surgery to place the HAI pump

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrahepatic Infusion Procedure
Description: Undergo HAI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study: NCT06382311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_Dose level 2
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_Dose level 2
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_Dose level 2
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_Dose level 2
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_ Dose level 3.
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_ Dose level 3.
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
Study: NCT05601830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QN-030a
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lympho-conditioning Agent
Study: NCT06382311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_ Dose level 3.
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_ Dose level 3.
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_ Dose level 3.
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_ Dose level 3.
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_ Dose level 3.
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Pandemic mRNA_ Dose level 3.
Description: 2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
Study: NCT06120699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with 360 degree expanded diaphragm exercises
Description: Women in this group will be taught 360-degree expanded diaphragm exercises with the Ohmbelt device. Two Ohmbelt devices will be used in this study. The anterior sensor will be placed in the inguinal cavity to visualize the expansion of the anterior abdominal wall, and the posterior sensor will be placed contralaterally in the upper lumbar triangle to visualize the expansion of the posterior wall. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training with standard diaphragm exercises
Description: Women in this group will be taught standard diaphragm exercises. In the supine position, with the head and knees supported by a pillow, the patient will first be asked to close his or her eyes to focus. With one hand on the chest and the other hand on the abdomen, Take a deep breath through your nose and direct all the air as much as possible under your lower hand. inflate your belly. Now exhale all the air slowly through your mouth. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied.
Study: NCT05695911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Limb Load Biofeedback Training Intervention
Description: Loadsol data will be used to inform the EXP telehealth sessions, as the interventionist guides the participant to self-monitor their movement, problem solve movement patterns that promote asymmetrical limb loading, and create weekly action plans for improving limb load symmetry. Weekly goals will be made in the context of functional task progression over the 40-week intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group. The CTL group sessions will include a review of the standard of care home-exercises, a summary of healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use, home safety).
Study: NCT05461417

Intervention type: DEVICE
Intervention: D-SAD
Description: Patients equipped with Panthera D-SAD® orthosis will be recruited.
Study: NCT05949242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI canaloplasty
Description: OMNI device is used to catheterize Schlemm's canal for 180 degrees and perform canaloplasty. Viscoelastic is eluded upon retraction of the catheter performing viscodilation of the canal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI canaloplasty
Description: OMNI device is used to catheterize Schlemm's canal for 180 degrees and perform canaloplasty. Viscoelastic is eluded upon retraction of the catheter performing viscodilation of the canal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrus microstent
Description: Hydrus stent is introduced into Schlemm's canal to scaffold open the canal
Study: NCT04841408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling
Description: Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
Study: NCT06101992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesoglycan
Description: Mesoglycan capsules 50 mg are composed by heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine
Study: NCT06382311

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.
Study: NCT06226701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryolipolysis device
Description: -Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryolipolysis device
Description: -Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months.
Study: NCT04190563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain De-Catastrophizing
Description: Experimenter-administered education and skill practice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pain Education
Description: Experimenter-administered education.